Get the Stockscreener App
19.64
7.84%
-1.67
Pre-market:
19.69
0.05
+0.25%
Adma Biologics Inc stock is traded at $19.64, with a volume of 5.78M.
It is down -7.84% in the last 24 hours and down -0.81% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$21.31
Open:
$21.15
24h Volume:
5.78M
Relative Volume:
2.02
Market Cap:
$4.99B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
23.95
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
-6.07%
1M Performance:
-0.81%
6M Performance:
+25.74%
1Y Performance:
+213.24%
1-Day Range:
$18.80
$21.59
1-Week Range:
$18.80
$22.25
52-Week Range:
$6.19
$23.64
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
19.64 | 4.99B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Why ADMA Biologics Inc. (ADMA) Performed Worst On Monday? - Insider Monkey
10 Firms Mirror Wall Street Bloodbath - Insider Monkey
Press Release Distribution & PR Platform - ACCESS Newswire
How to Take Advantage of moves in (ADMA) - news.stocktradersdaily.com
Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
ADMA Biologics (ADMA): Among Louis Navellier’s New Stock Picks - Yahoo Finance
Adma Biologics CEO Adam Grossman sells $450,660 in stock By Investing.com - Investing.com Canada
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? - MSN
Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? - Insider Monkey
10 Firms End Stronger on Tuesday - Insider Monkey
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average - Zacks Investment Research
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last? - Nasdaq
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Why ADMA Biologics Inc. (ADMA) Skyrocketed On Monday? - Insider Monkey
Biotech Stocks Dominate Monday’s Top 10 Gainers - Insider Monkey
Axogen and ADMA Biologics expect low to zero impact from recent tariffs - MSN
ADMA Biologics says tariffs will not impact operations due to fully U.S.-based supply chain - ROI-NJ
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect? - MSN
Sector Update: Health Care - MarketScreener
ADMA Biologics Says Tariffs Not Likely to Impact Supply Chain, Production Operations - MarketScreener
Adma BiologicsTariffs Expected To Have No Impact On Adma's Operations - MarketScreener
ADMA Biologics Statement on Tariffs - GlobeNewswire
ADMA's All-American Operations Shield Company From New Tariff Storm - Stock Titan
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know - MSN
Trading (ADMA) With Integrated Risk Controls - news.stocktradersdaily.com
Ensign Group Invests in Growth With New Facility Acquisitions - TradingView
ADMA STOCK DROP ALERT: ADMA Biologics, Inc. Stock Drops over 20%; BFA Law Initiates Securities Fraud Investigation and Urges Investors with Losses to Contact the Firm (Nasdaq:ADMA) - ACCESS Newswire
What's Driving the Market Sentiment Around ADMA Biologics? - Benzinga
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest? - Yahoo Finance
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know - Yahoo Finance
How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback - MSN
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains? - MSN
Adma Biologics CEO Adam Grossman sells $397,320 in stock By Investing.com - Investing.com Australia
Adma Biologics CEO Adam Grossman sells $397,320 in stock - Investing.com
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock - Yahoo Finance
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential - Seeking Alpha
ADMA Stock Builds A Base As Profits Continue To Soar - MSN
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
Pulse of the Market: Wednesday’s 10 Top Performers - Insider Monkey
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
Why ADMA Biologics Inc. (ADMA) Went Up On Wednesday? - Yahoo Finance
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):